These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34674319)

  • 1. COVID-19-associated mucormycosis, diabetes and steroid therapy: Experience in a single centre in Western Mexico.
    Guzmán-Castro S; Chora-Hernandez LD; Trujillo-Alonso G; Calvo-Villalobos I; Sanchez-Rangel A; Ferrer-Alpuin E; Ruiz-Jimenez M; Corzo-Leon DE
    Mycoses; 2022 Jan; 65(1):65-70. PubMed ID: 34674319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India.
    Dravid A; Kashiva R; Khan Z; Bande B; Memon D; Kodre A; Mane M; Pawar V; Patil D; Kalyani S; Raut P; Bapte M; Saldanha C; Chandak D; Patil T; Reddy S; Bhayani K; Suresh L; Dillibabu V; Srivastava S; Khandelwal S; More S; Shakeel A; Pawar M; Nande P; Harshe A; Kadam S; Hallikar S; Kamal N; Andrabi D; Bodhale S; Raut A; Chandrashekhar S; Raman C; Mahajan U; Joshi G; Mane D
    Mycoses; 2022 May; 65(5):526-540. PubMed ID: 35212032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for COVID-19 associated mucormycosis in India: A case control study.
    Patel AK; Bakshi H; Shah K; Patel S; Patel T; Patel K; Patel KK
    Med Mycol; 2022 Jul; 60(7):. PubMed ID: 35709394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronavirus disease-associated mucormycosis (CAM): A case control study during the outbreak in India.
    Wasiq M; K R; Gn A
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 associated mucormycosis - An emerging threat.
    Chao CM; Lai CC; Yu WL
    J Microbiol Immunol Infect; 2022 Apr; 55(2):183-190. PubMed ID: 35074291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors of COVID-19 Associated Mucormycosis (CAM) in Iranian Patients: A Single-Center Retrospective Study.
    Tavakolpour S; Irani S; Yekaninejad MS; Alimardi M; Hasibi M; Abdollahi H; Kazemi MA; Lotfi M; Shahbazian H; Nazemian Yazdi NA; Samimiardestani S; Firouzifar M; Farahbakhsh F; Mirzaee Goodarzi M; Feiz F; Salehinia F
    Mycopathologia; 2022 Dec; 187(5-6):469-479. PubMed ID: 36202942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: Clinical Features, Antifungal Susceptibility, Management and Outcome in a Tertiary Hospital in Iran.
    Abdorahimi M; Pakdel F; Salehi M; Alcazar-Fuoli L; Hashemi SJ; Daie Ghazvini R; Ahmadkhani F; Ahmadikia K; Abdollahi A; Debran JCS; Tabari A; Farrokh F; Mousavand A; Afarinesh Khaki P; Salami Khaneshan A; Ibrahim AS; Khodavaisy S
    Mycopathologia; 2023 Oct; 188(5):783-792. PubMed ID: 37672164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucormycosis and COVID-19: An epidemic within a pandemic in India.
    Selarka L; Sharma S; Saini D; Sharma S; Batra A; Waghmare VT; Dileep P; Patel S; Shah M; Parikh T; Darji P; Patel A; Goswami G; Shah A; Shah S; Lathiya H; Shah M; Sharma P; Chopra S; Gupta A; Jain N; Khan E; Sharma VK; Sharma AK; Chan ACY; Ong JJY
    Mycoses; 2021 Oct; 64(10):1253-1260. PubMed ID: 34255907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.
    Patel A; Agarwal R; Rudramurthy SM; Shevkani M; Xess I; Sharma R; Savio J; Sethuraman N; Madan S; Shastri P; Thangaraju D; Marak R; Tadepalli K; Savaj P; Sunavala A; Gupta N; Singhal T; Muthu V; Chakrabarti A;
    Emerg Infect Dis; 2021 Sep; 27(9):2349-2359. PubMed ID: 34087089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucormycosis an added burden to Covid-19 Patients: An in-depth systematic review.
    Shah NN; Khan Z; Ahad H; Elderdery AY; Alomary MN; Atwah B; Alhindi Z; Alsugoor MH; Elkhalifa AME; Nabi S; Bashir SM; Yaqub T; Rather GA; Ansari MA
    J Infect Public Health; 2022 Nov; 15(11):1299-1314. PubMed ID: 36279686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients.
    Bansal SB; Rana A; Babras M; Yadav D; Jha P; Jain M; Sethi SK
    Transpl Infect Dis; 2022 Apr; 24(2):e13777. PubMed ID: 34932870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID associated mucormycosis: A preliminary study from a dedicated COVID Hospital in Delhi.
    Meher R; Wadhwa V; Kumar V; Shisha Phanbuh D; Sharma R; Singh I; Rathore PK; Goel R; Arora R; Garg S; Kumar S; Kumar J; Agarwal M; Singh M; Khurana N; Sagar T; Manchanda V; Saxena S
    Am J Otolaryngol; 2022; 43(1):103220. PubMed ID: 34547717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucormycosis in the COVID-19 Environment: A Multifaceted Complication.
    Sharma R; Kumar P; Rauf A; Chaudhary A; Prajapati PK; Emran TB; Gonçalves Lima CM; Conte-Junior CA
    Front Cell Infect Microbiol; 2022; 12():937481. PubMed ID: 35923801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries.
    Rudramurthy SM; Hoenigl M; Meis JF; Cornely OA; Muthu V; Gangneux JP; Perfect J; Chakrabarti A;
    Mycoses; 2021 Sep; 64(9):1028-1037. PubMed ID: 34133816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India.
    Mishra Y; Prashar M; Sharma D; Akash ; Kumar VP; Tilak TVSVGK
    Diabetes Metab Syndr; 2021; 15(4):102196. PubMed ID: 34246939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First report of COVID-19-associated rhino-orbito-cerebral mucormycosis in pediatric patients with type 1 diabetes mellitus.
    Diwakar J; Samaddar A; Konar SK; Bhat MD; Manuel E; Hb V; Bn N; Parveen A; Hajira SN; Srinivas D; S N
    J Mycol Med; 2021 Dec; 31(4):101203. PubMed ID: 34517273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19-associated mucormycosis in India: Why such an outbreak?
    Pasquier G
    J Mycol Med; 2023 Aug; 33(3):101393. PubMed ID: 37182234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhino-Orbital Cerebral Mucormycosis in Non-Diabetic Patients with COVID-19.
    Elhamamsy S; Bayer T; Al-Kaffas M; Hatahet S; Grover M; Samdhani S; Nanda A; Gravenstein S
    R I Med J (2013); 2021 Oct; 104(8):19-21. PubMed ID: 34582509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran.
    Pakdel F; Ahmadikia K; Salehi M; Tabari A; Jafari R; Mehrparvar G; Rezaie Y; Rajaeih S; Alijani N; Barac A; Abdollahi A; Khodavaisy S
    Mycoses; 2021 Oct; 64(10):1238-1252. PubMed ID: 34096653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results from a national survey on COVID-19-associated mucormycosis in Germany: 13 patients from six tertiary hospitals.
    Seidel D; Simon M; Sprute R; Lubnow M; Evert K; Speer C; Seeßle J; Khatamzas E; Merle U; Behrens C; Blau IW; Enghard P; Haas CS; Steinmann J; Kurzai O; Cornely OA
    Mycoses; 2022 Jan; 65(1):103-109. PubMed ID: 34655486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.